{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:55:43Z","timestamp":1791179743237,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":464,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1038\/mt.2015.87","type":"journal-article","created":{"date-parts":[[2015,4,27]],"date-time":"2015-04-27T13:25:16Z","timestamp":1430141116000},"page":"1169-1181","source":"Crossref","is-referenced-by-count":37,"title":["Coformulation of a Novel Human \u03b1 -Galactosidase A With the Pharmacological Chaperone AT1001 Leads to Improved Substrate Reduction in Fabry Mice"],"prefix":"10.1016","volume":"23","author":[{"given":"Su","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nastry","family":"Brignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Hamler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriane","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Frascella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Soska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anadina","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehito","family":"Yasukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Shardlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Churchill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol","family":"Ketkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elfrida R","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Hirato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie","family":"Fowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J","family":"Valenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richie","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2015.87_bib1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2015.87_bib2","series-title":"\u03b1-galactosidase A deficiency: Fabry disease. The Metabolic and Molecular Bases of Inherited Disease","first-page":"3733","author":"Desnick","year":"2001"},{"key":"10.1038\/mt.2015.87_bib3","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00428-007-0468-6","article-title":"Cellular and tissue localization of globotriaosylceramide in Fabry disease","volume":"451","author":"Askari","year":"2007","journal-title":"Virchows Arch"},{"key":"10.1038\/mt.2015.87_bib4","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2015.87_bib5","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"Rombach","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1038\/mt.2015.87_bib6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"Togawa","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2015.87_bib7","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.bbrc.2010.08.006","article-title":"Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease","volume":"399","author":"Togawa","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1038\/mt.2015.87_bib8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase \u00bd clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1038\/mt.2015.87_bib9","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1038\/mt.2015.87_bib10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson\u2013Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"10.1038\/mt.2015.87_bib11","unstructured":"Schiffmann R, Germain DP, Castelli J, Shenker A, Lockhart DJ. 2008 768\/T. Phase 2 clinical trials of the pharmacological chaperone AT1001 for the treatment of Fabry disease. Presented at the American Society of Human Genetics Conference, Philadelphia, 11\u201315 November 2008"},{"key":"10.1038\/mt.2015.87_bib12","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/mt.2015.87_bib13","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int"},{"key":"10.1038\/mt.2015.87_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"B\u00e9nichou","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2015.87_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/GIM.0b013e318170f868","article-title":"Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme","volume":"10","author":"Bodensteiner","year":"2008","journal-title":"Genet Med"},{"key":"10.1038\/mt.2015.87_bib16","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1365-2125.2009.03501.x","article-title":"Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies","volume":"68","author":"Tesmoingt","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1038\/mt.2015.87_bib17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0076-6879(03)01069-3","article-title":"Cell-based screening of active-site specific chaperone for the treatment of Fabry disease","volume":"363","author":"Fan","year":"2003","journal-title":"Methods Enzymol"},{"key":"10.1038\/mt.2015.87_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/adt.2011.0370","article-title":"Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders","volume":"9","author":"Valenzano","year":"2011","journal-title":"Assay Drug Dev Technol"},{"key":"10.1038\/mt.2015.87_bib19","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S0957-4166(00)00113-0","article-title":"Sugar-mimic glycosidase inhibitors: natural occurrence, biological activity and prospects for therapeutic application","volume":"11","author":"Asano","year":"2000","journal-title":"Tetrahedron: Asymmetry"},{"key":"10.1038\/mt.2015.87_bib20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbrc.2007.05.082","article-title":"Screening for pharmacological chaperones in Fabry disease","volume":"359","author":"Shin","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1038\/mt.2015.87_bib21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat Med"},{"key":"10.1038\/mt.2015.87_bib22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1096\/fj.04-2375com","article-title":"A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder","volume":"19","author":"Yam","year":"2005","journal-title":"FASEB J"},{"key":"10.1038\/mt.2015.87_bib23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines","volume":"32","author":"Benjamin","year":"2009","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/mt.2015.87_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/mt.2009.220","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease","volume":"18","author":"Khanna","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2015.87_bib25","doi-asserted-by":"crossref","first-page":"C1076","DOI":"10.1152\/ajpcell.00426.2005","article-title":"Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants","volume":"290","author":"Yam","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1038\/mt.2015.87_bib26","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1124\/jpet.108.149054","article-title":"Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease","volume":"328","author":"Ishii","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1038\/mt.2015.87_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1750-1172-7-91","article-title":"Safety and pharmacodynamic effects of a pharmacological chaperone on \u03b1-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies","volume":"7","author":"Germain","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1038\/mt.2015.87_bib28","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymgme.2013.01.009","article-title":"A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects","volume":"109","author":"Giugliani","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2015.87_bib29","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1742-4658.2010.07588.x","article-title":"The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase","volume":"277","author":"Khanna","year":"2010","journal-title":"FEBS J"},{"key":"10.1038\/mt.2015.87_bib30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/cpdd.1","article-title":"Pharmacokinetics and safety of migalastat HCl and effects on agalsidase activity in healthy volunteers","volume":"2","author":"Johnson","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1038\/mt.2015.87_bib31","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbrc.2008.02.125","article-title":"Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase","volume":"369","author":"Shen","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1038\/mt.2015.87_bib32","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/mt.2009.53","article-title":"The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts","volume":"17","author":"Porto","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2015.87_bib33","doi-asserted-by":"crossref","first-page":"e40776","DOI":"10.1371\/journal.pone.0040776","article-title":"The pharmacological chaperone AT2220 increases recombinant human acid \u03b1-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease","volume":"7","author":"Khanna","year":"2012","journal-title":"PLoS One"},{"key":"10.1038\/mt.2015.87_bib34","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/mt.2011.271","article-title":"Co-administration with the pharmacological chaperone AT1001 increases recombinant human \u03b1-galactosidase A tissue uptake and improves substrate reduction in Fabry mice","volume":"20","author":"Benjamin","year":"2012","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2015.87_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134341","article-title":"Oral migalastat HCl leads to greater systemic exposure and tissue levels of active \u03b1-galactosidase A in Fabry patients when co-administered with infused agalsidase","author":"Warnock","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1038\/mt.2015.87_bib36","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/humu.21121","article-title":"The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase","volume":"30","author":"Flanagan","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1038\/mt.2015.87_bib37","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10545-011-9424-3","article-title":"Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease","volume":"35","author":"Porto","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/mt.2015.87_bib38","first-page":"S96","article-title":"An ongoing phase 2A study to investigate the effect of AT2220 (duvoglustat HCl) on the pharmacokinetics of acid alpha-glucosidase in subjectswith Pompe disease: preliminary results","volume":"35","author":"Johnson","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/mt.2015.87_bib39","first-page":"S158","article-title":"Development of a next-generation ERT, ATB100C, for Fabry disease","volume":"37","author":"Hughes","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/mt.2015.87_bib40","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ymgme.2011.12.012","article-title":"Mannose-6-phosphate pathway: a review on its role in lysosomal function and dysfunction","volume":"105","author":"Coutinho","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2015.87_bib41","first-page":"602","article-title":"Endocytosis of lysosomal alpha-galactosidase A by cultured fibroblasts from patients with Fabry disease","volume":"34","author":"Mayes","year":"1982","journal-title":"Am J Hum Genet"},{"key":"10.1038\/mt.2015.87_bib42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2015.87_bib43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1038\/mt.2015.87_bib44","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/mt.2015.87_bib45","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00428-008-0586-9","article-title":"Replacement of alpha-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients","volume":"452","author":"Keslov\u00e1-Vesel\u00edkov\u00e1","year":"2008","journal-title":"Virchows Arch"},{"key":"10.1038\/mt.2015.87_bib46","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00428-005-0089-x","article-title":"Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement","volume":"448","author":"Schiffmann","year":"2006","journal-title":"Virchows Arch"},{"key":"10.1038\/mt.2015.87_bib47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ymgme.2007.10.108","article-title":"Pathology of Fabry nephropathy: renal fibrosis may begin in adolescence","volume":"93","author":"Thurberg","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2015.87_bib48","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","volume":"13","author":"Lee","year":"2003","journal-title":"Glycobiology"},{"key":"10.1038\/mt.2015.87_bib49","first-page":"S161","article-title":"Migalastat reduces plasma globotriaosylsphingosine (lyso-Gb3) in Fabry patients: results from the facets phase 3 study","volume":"37","author":"Benjamin","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/mt.2015.87_bib50","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/humu.21530","article-title":"A pharmacogenetic approach to identify mutant forms of \u03b1-galactosidase A that respond to a pharmacological chaperone for Fabry disease","volume":"32","author":"Wu","year":"2011","journal-title":"Hum Mutat"},{"key":"10.1038\/mt.2015.87_bib51","first-page":"S190","article-title":"A pharmacogenetic approach to identify mutant forms of \u03b1-galactosidase A that respond to a pharmacological chaperone for Fabry disease","volume":"34","author":"Wu","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/mt.2015.87_bib52","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/nprot.2007.321","article-title":"The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability","volume":"2","author":"Niesen","year":"2007","journal-title":"Nat Protoc"},{"key":"10.1038\/mt.2015.87_bib53","doi-asserted-by":"crossref","first-page":"e57631","DOI":"10.1371\/journal.pone.0057631","article-title":"Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients","volume":"8","author":"Young-Gqamana","year":"2013","journal-title":"PLoS One"},{"key":"10.1038\/mt.2015.87_bib54","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/ejoc.201001690","article-title":"A concise synthesis of globotriaosylsphingosine","volume":"2011","author":"Gold","year":"2011","journal-title":"Eur J Org Chem"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616301484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616301484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T03:21:04Z","timestamp":1537672864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616301484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S1525001616301484"],"URL":"https:\/\/doi.org\/10.1038\/mt.2015.87","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}